Volume | 2,069 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Recursion Pharmaceuticals Inc | RXRX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
7.47 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
61 | 2,069 | - | 4.54 - 16.745 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
06:48:06 | 1 | $ 7.50 | USD |
Recursion Pharmaceuticals (RXRX) Options Flow Summary
Recursion Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.75B | 234.65M | - | 44.58M | -328.07M | -1.40 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Recursion Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RXRX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 8.65 | 8.94 | 7.43 | 7.99 | 3,743,023 | -1.14 | -13.18% |
1 Month | 11.20 | 11.4498 | 7.43 | 9.24 | 4,456,339 | -3.69 | -32.95% |
3 Months | 10.47 | 15.74 | 7.43 | 11.40 | 6,439,265 | -2.96 | -28.27% |
6 Months | 6.49 | 15.74 | 4.97 | 10.11 | 5,768,200 | 1.02 | 15.72% |
1 Year | 6.31 | 16.745 | 4.54 | 10.26 | 5,155,213 | 1.20 | 19.02% |
3 Years | 28.90 | 42.81 | 4.54 | 11.05 | 2,390,908 | -21.39 | -74.01% |
5 Years | 30.00 | 42.81 | 4.54 | 11.09 | 2,393,032 | -22.49 | -74.97% |
Recursion Pharmaceuticals Description
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. |